<p>Apellis Pharmaceuticals, Inc.（納斯達克代碼：APLS - 獲取免費報告）在週五的交易中股價上漲了 6.2%。該股票最高交易價為 23.08 美元，最後交易價為 23.5760 美元。在交易中大約有 222,080 股易手，較日均成交量 2,352,329 股下降了 91%。該股票此前收盤價為 22.19 美元。</p>
<h2>分析師評級調整</h2>
<ul>
<li>Beam Therapeutics 因基因治療許可支付而大幅上漲</li>
</ul>
<p>幾位研究分析師對該公司發表了看法。富國銀行於 10 月 15 日星期三發佈研究報告，開始對 Apellis Pharmaceuticals 進行覆蓋。他們給予該股票 “增持” 評級，目標價為 32.00 美元。HC Wainwright 在 10 月 31 日星期五的報告中將 Apellis Pharmaceuticals 的目標價從 57.00 美元下調至 45.00 美元，並給予該公司 “買入” 評級。Wolfe Research 於 11 月 6 日星期四發佈研究報告，開始對 Apellis Pharmaceuticals 的股票進行覆蓋。他們對該股票給予 “同行表現” 評級。華爾街 Zen 在 11 月 8 日星期六的研究報告中將 Apellis Pharmaceuticals 的股票評級從 “持有” 上調至 “買入”。最後，瑞穗證券在 11 月 3 日星期一的研究報告中將 Apellis Pharmaceuticals 的目標價從 24.00 美元下調至 19.00 美元，並給予該公司 “中性” 評級。九位研究分析師對該股票給予 “買入” 評級，七位給予 “持有” 評級，兩位給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的平均評級為 “持有”，共識目標價為 33.06 美元。</p>
<p><strong>查看我們對 APLS 的最新分析</strong></p>
<h2>Apellis Pharmaceuticals 價格表現</h2>
<ul>
<li>小型股是否預示市場下跌？</li>
</ul>
<p>該股票的 50 日移動平均價格為 22.89 美元，200 日移動平均價格為 22.07 美元。該公司的債務與股本比率為 0.90，速動比率為 3.10，流動比率為 3.54。該公司的市值為 30.1 億美元，市盈率為 76.92，貝塔值為 0.37。</p>
<p>Apellis Pharmaceuticals（納斯達克代碼：APLS - 獲取免費報告）於 10 月 30 日星期四發佈了季度財報。該公司報告季度每股收益為 1.67 美元，超出分析師一致預期的 1.03 美元，超出幅度為 0.64 美元。Apellis Pharmaceuticals 的淨利潤率為 4.43%，股本回報率為 18.94%。該公司季度收入為 4.5858 億美元，而一致預期為 3.6458 億美元。去年同期，該公司的每股收益為（0.46）美元。該公司的收入同比增長了 133.0%。整體來看，股票分析師預測 Apellis Pharmaceuticals, Inc.在當前財年將發佈-1.7 美元的每股收益。</p>
<h2>內部人士買賣</h2>
<p>在其他 Apellis Pharmaceuticals 的新聞中，董事 A. Sinclair Dunlop 於 10 月 10 日星期五出售了 31,092 股該公司的股票。該股票以平均價格 23.72 美元出售，總交易額為 737,502.24 美元。出售後，該董事直接持有該公司 3,837 股，價值約 91,013.64 美元。此次交易使其持股減少了 89.01%。該交易已在向證券交易委員會提交的文件中披露，您可以通過此鏈接訪問。此外，首席財務官 Timothy Eugene Sullivan 於 10 月 21 日星期二出售了 10,000 股該公司的股票。該股票以平均價格 28.03 美元出售，總價值為 280,300.00 美元。出售完成後，首席財務官直接持有該公司 110,936 股，價值為 3,109,536.08 美元。此次交易使其持股減少了 8.27%。該交易的披露信息可在 SEC 文件中找到。內部人士在上個季度共出售了 87,373 股公司股票，價值 2,084,036 美元。公司內部人士持有公司股票的 6.50%。</p>
<h2>機構投資者對 Apellis Pharmaceuticals 的看法</h2>
<p>幾家機構投資者和對沖基金最近對該公司的持倉進行了調整。Corton Capital Inc.在第二季度收購了 Apellis Pharmaceuticals 的新頭寸，價值約 364,000 美元。Woodline Partners LP 在第一季度增加了對 Apellis Pharmaceuticals 股票的持股，增幅為 15.5%。Woodline Partners LP 現在持有 218,850 股該公司的股票，價值 4,786,000 美元，此前在上個季度又購買了 29,373 股。Wealth Enhancement Advisory Services LLC 在第二季度增加了對 Apellis Pharmaceuticals 股票的持股，增幅為 43.5%。Wealth Enhancement Advisory Services LLC 現在持有 100,666 股該公司的股票，價值 1,838,000 美元，此前在上個季度又購買了 30,507 股。Bayforest Capital Ltd 在第一季度增加了對 Apellis Pharmaceuticals 股票的持股，增幅為 431.9%。Bayforest Capital Ltd 現在持有 52,338 股該公司的股票，價值 1,145,000 美元，此前在上個季度又購買了 42,499 股。最後，Pallas Capital Advisors LLC 在第二季度增加了對 Apellis Pharmaceuticals 股票的持股，增幅為 29.0%。Pallas Capital Advisors LLC 現在持有 54,849 股該公司的股票，價值 949,000 美元，此前在上個季度又購買了 12,315 股。目前 96.29% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Apellis Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Apellis Pharmaceuticals, Inc.是一家商業階段的生物製藥公司，專注於通過抑制補體系統來發現、開發和商業化治療自身免疫和炎症疾病的化合物。它提供 EMPAVELI 用於治療陣發性夜間血紅蛋白尿、C3 腎小管病和免疫複合物膜增生性腎小管炎，以及與造血幹細胞移植相關的血栓性微血管病；並提供 SYFOVRE 用於治療與年齡相關的黃斑變性和地理性萎縮（GA）引起的地理性萎縮。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們認為比 Apellis Pharmaceuticals 更好的股票</li>
<li>上海證券交易所綜合指數是什麼？</li>
<li>Kroger 股票分析：數字轉型、股息安全性與 2026 年增長計劃</li>
<li>科技股解析：你需要了解的科技知識</li>
<li>加密礦工會轉向人工智能嗎？三大關鍵參與者的最新動態</li>
<li>什麼是盈利驚喜？</li>
<li>Salesforce 股票像彈簧一樣蓄勢待發，準備反彈</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Apellis Pharmaceuticals 嗎？</h2>
<p>在你考慮 Apellis Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Apellis Pharmaceuticals 並不在名單上。</p>
<p>雖然 Apellis Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

APLS

<p>Apellis Pharmaceuticals（納斯達克代碼：APLS）股票上漲 6.2%，至 23.5760 美元，交易量顯著低於平均水平。分析師的評級不一，普遍目標價為 33.06 美元。最近的內部交易包括董事 Dunlop 和首席財務官 Sullivan 的出售。機構投資者已調整其持倉，Woodline Partners 和 Wealth Enhancement Advisory Services 的增持尤為顯著。公司報告了強勁的季度收益，收入同比增長 133%</p>

<p>Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) shares were up 6.2% during trading on Friday . The stock traded as high as $23.08 and last traded at $23.5760. Approximately 222,080 shares changed hands during trading, a decline of 91% from the average daily volume of 2,352,329 shares. The stock had previously closed at $22.19.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.（納斯達克代碼：APLS - 獲取免費報告）在週五的交易中股價上漲了 6.2%。該股票最高交易價為 23.08 美元，最後交易價為 23.5760 美元。在交易中大約有 222,080 股易手，較日均成交量 2,352,329 股下降了 91%。該股票此前收盤價為 22.19 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治療許可支付而大幅上漲</li>
</ul>
</div><p>Several research analysts have weighed in on the company. Wells Fargo &amp; Company began coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 15th. They issued an &#34;overweight&#34; rating and a $32.00 target price on the stock. HC Wainwright decreased their price target on Apellis Pharmaceuticals from $57.00 to $45.00 and set a &#34;buy&#34; rating for the company in a report on Friday, October 31st. Wolfe Research started coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, November 6th. They issued a &#34;peer perform&#34; rating on the stock. Wall Street Zen upgraded shares of Apellis Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, November 8th. Finally, Mizuho reduced their target price on shares of Apellis Pharmaceuticals from $24.00 to $19.00 and set a &#34;neutral&#34; rating for the company in a research note on Monday, November 3rd. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of &#34;Hold&#34; and a consensus target price of $33.06.</p>
<div class="lb-trans"><p>幾位研究分析師對該公司發表了看法。富國銀行於 10 月 15 日星期三發佈研究報告，開始對 Apellis Pharmaceuticals 進行覆蓋。他們給予該股票 “增持” 評級，目標價為 32.00 美元。HC Wainwright 在 10 月 31 日星期五的報告中將 Apellis Pharmaceuticals 的目標價從 57.00 美元下調至 45.00 美元，並給予該公司 “買入” 評級。Wolfe Research 於 11 月 6 日星期四發佈研究報告，開始對 Apellis Pharmaceuticals 的股票進行覆蓋。他們對該股票給予 “同行表現” 評級。華爾街 Zen 在 11 月 8 日星期六的研究報告中將 Apellis Pharmaceuticals 的股票評級從 “持有” 上調至 “買入”。最後，瑞穗證券在 11 月 3 日星期一的研究報告中將 Apellis Pharmaceuticals 的目標價從 24.00 美元下調至 19.00 美元，並給予該公司 “中性” 評級。九位研究分析師對該股票給予 “買入” 評級，七位給予 “持有” 評級，兩位給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的平均評級為 “持有”，共識目標價為 33.06 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on APLS</strong></p>
<div class="lb-trans"><p><strong>查看我們對 APLS 的最新分析</strong></p>
</div><h2>Apellis Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 價格表現</h2>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否預示市場下跌？</li>
</ul>
</div><p>The stock's fifty day moving average price is $22.89 and its 200-day moving average price is $22.07. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The firm has a market cap of $3.01 billion, a PE ratio of 76.92 and a beta of 0.37.</p>
<div class="lb-trans"><p>該股票的 50 日移動平均價格為 22.89 美元，200 日移動平均價格為 22.07 美元。該公司的債務與股本比率為 0.90，速動比率為 3.10，流動比率為 3.54。該公司的市值為 30.1 億美元，市盈率為 76.92，貝塔值為 0.37。</p>
</div><p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings data on Thursday, October 30th. The company reported $1.67 EPS for the quarter, topping analysts' consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The firm had revenue of $458.58 million for the quarter, compared to the consensus estimate of $364.58 million. During the same quarter in the previous year, the firm earned ($0.46) earnings per share. The firm's revenue was up 133.0% on a year-over-year basis. As a group, equities analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals（納斯達克代碼：APLS - 獲取免費報告）於 10 月 30 日星期四發佈了季度財報。該公司報告季度每股收益為 1.67 美元，超出分析師一致預期的 1.03 美元，超出幅度為 0.64 美元。Apellis Pharmaceuticals 的淨利潤率為 4.43%，股本回報率為 18.94%。該公司季度收入為 4.5858 億美元，而一致預期為 3.6458 億美元。去年同期，該公司的每股收益為（0.46）美元。該公司的收入同比增長了 133.0%。整體來看，股票分析師預測 Apellis Pharmaceuticals, Inc.在當前財年將發佈-1.7 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣</h2>
</div><p>In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 31,092 shares of the business's stock in a transaction on Friday, October 10th. The stock was sold at an average price of $23.72, for a total transaction of $737,502.24. Following the sale, the director directly owned 3,837 shares in the company, valued at approximately $91,013.64. The trade was a 89.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CFO Timothy Eugene Sullivan sold 10,000 shares of the company's stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $28.03, for a total value of $280,300.00. Following the completion of the sale, the chief financial officer directly owned 110,936 shares in the company, valued at $3,109,536.08. This trade represents a 8.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 87,373 shares of company stock worth $2,084,036 in the last quarter. Company insiders own 6.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Apellis Pharmaceuticals 的新聞中，董事 A. Sinclair Dunlop 於 10 月 10 日星期五出售了 31,092 股該公司的股票。該股票以平均價格 23.72 美元出售，總交易額為 737,502.24 美元。出售後，該董事直接持有該公司 3,837 股，價值約 91,013.64 美元。此次交易使其持股減少了 89.01%。該交易已在向證券交易委員會提交的文件中披露，您可以通過此鏈接訪問。此外，首席財務官 Timothy Eugene Sullivan 於 10 月 21 日星期二出售了 10,000 股該公司的股票。該股票以平均價格 28.03 美元出售，總價值為 280,300.00 美元。出售完成後，首席財務官直接持有該公司 110,936 股，價值為 3,109,536.08 美元。此次交易使其持股減少了 8.27%。該交易的披露信息可在 SEC 文件中找到。內部人士在上個季度共出售了 87,373 股公司股票，價值 2,084,036 美元。公司內部人士持有公司股票的 6.50%。</p>
</div><h2>Institutional Investors Weigh In On Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Apellis Pharmaceuticals 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in the business. Corton Capital Inc. acquired a new position in Apellis Pharmaceuticals during the second quarter worth about $364,000. Woodline Partners LP increased its stake in shares of Apellis Pharmaceuticals by 15.5% during the 1st quarter. Woodline Partners LP now owns 218,850 shares of the company's stock worth $4,786,000 after purchasing an additional 29,373 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of Apellis Pharmaceuticals by 43.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 100,666 shares of the company's stock worth $1,838,000 after purchasing an additional 30,507 shares in the last quarter. Bayforest Capital Ltd raised its position in shares of Apellis Pharmaceuticals by 431.9% during the 1st quarter. Bayforest Capital Ltd now owns 52,338 shares of the company's stock worth $1,145,000 after purchasing an additional 42,499 shares during the last quarter. Finally, Pallas Capital Advisors LLC raised its position in shares of Apellis Pharmaceuticals by 29.0% during the 2nd quarter. Pallas Capital Advisors LLC now owns 54,849 shares of the company's stock worth $949,000 after purchasing an additional 12,315 shares during the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近對該公司的持倉進行了調整。Corton Capital Inc.在第二季度收購了 Apellis Pharmaceuticals 的新頭寸，價值約 364,000 美元。Woodline Partners LP 在第一季度增加了對 Apellis Pharmaceuticals 股票的持股，增幅為 15.5%。Woodline Partners LP 現在持有 218,850 股該公司的股票，價值 4,786,000 美元，此前在上個季度又購買了 29,373 股。Wealth Enhancement Advisory Services LLC 在第二季度增加了對 Apellis Pharmaceuticals 股票的持股，增幅為 43.5%。Wealth Enhancement Advisory Services LLC 現在持有 100,666 股該公司的股票，價值 1,838,000 美元，此前在上個季度又購買了 30,507 股。Bayforest Capital Ltd 在第一季度增加了對 Apellis Pharmaceuticals 股票的持股，增幅為 431.9%。Bayforest Capital Ltd 現在持有 52,338 股該公司的股票，價值 1,145,000 美元，此前在上個季度又購買了 42,499 股。最後，Pallas Capital Advisors LLC 在第二季度增加了對 Apellis Pharmaceuticals 股票的持股，增幅為 29.0%。Pallas Capital Advisors LLC 現在持有 54,849 股該公司的股票，價值 949,000 美元，此前在上個季度又購買了 12,315 股。目前 96.29% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Apellis Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.是一家商業階段的生物製藥公司，專注於通過抑制補體系統來發現、開發和商業化治療自身免疫和炎症疾病的化合物。它提供 EMPAVELI 用於治療陣發性夜間血紅蛋白尿、C3 腎小管病和免疫複合物膜增生性腎小管炎，以及與造血幹細胞移植相關的血栓性微血管病；並提供 SYFOVRE 用於治療與年齡相關的黃斑變性和地理性萎縮（GA）引起的地理性萎縮。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Apellis Pharmaceuticals</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>Kroger Stock Analysis: Digital Pivot, Dividend Safety &amp; 2026 Growth Plan</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>Will Crypto Miners Pivot to AI? Latest on 3 Key Players</li>
<li>What is an Earnings Surprise?</li>
<li>Salesforce Stock Is Coiled Like a Spring and Ready to Rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Apellis Pharmaceuticals 更好的股票</li>
<li>上海證券交易所綜合指數是什麼？</li>
<li>Kroger 股票分析：數字轉型、股息安全性與 2026 年增長計劃</li>
<li>科技股解析：你需要了解的科技知識</li>
<li>加密礦工會轉向人工智能嗎？三大關鍵參與者的最新動態</li>
<li>什麼是盈利驚喜？</li>
<li>Salesforce 股票像彈簧一樣蓄勢待發，準備反彈</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Apellis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Apellis Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Apellis Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Apellis Pharmaceuticals 並不在名單上。</p>
</div><p>While Apellis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Apellis Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Apellis Pharmaceuticals（納斯達克股票代碼：APLS）股價上漲 6.2% - 現在是否仍然值得購買？